In last trading session, Arcutis Biotherapeutics Inc (NASDAQ:ARQT) saw 4.73 million shares changing hands with its beta currently measuring 1.20. Company’s recent per share price level of $10.40 trading at $0.74 or 7.66% at ring of the bell on the day assigns it a market valuation of $1.22B. That closing price of ARQT’s stock is at a discount of -26.63% from its 52-week high price of $13.17 and is indicating a premium of 83.08% from its 52-week low price of $1.76. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.99 million shares which gives us an average trading volume of 2.05 million if we extend that period to 3-months.
For Arcutis Biotherapeutics Inc (ARQT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 3 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.36 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information
Upright in the green during last session for gaining 7.66%, in the last five days ARQT remained trading in the green while hitting it’s week-highest on Thursday, 11/07/24 when the stock touched $10.40 price level, adding 3.53% to its value on the day. Arcutis Biotherapeutics Inc’s shares saw a change of 221.98% in year-to-date performance and have moved 25.15% in past 5-day. Arcutis Biotherapeutics Inc (NASDAQ:ARQT) showed a performance of 6.12% in past 30-days. Number of shares sold short was 28.06 million shares which calculate 14.47 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 27.5 to the stock, which implies a rise of 62.18% to its current value. Analysts have been projecting 18 as a low price target for the stock while placing it at a high target of 51. It follows that stock’s current price would drop -73.08% in reaching the projected high whereas dropping to the targeted low would mean a loss of -73.08% for stock’s current value.
Arcutis Biotherapeutics Inc (ARQT) estimates and forecasts
Statistics highlight that Arcutis Biotherapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 29.68% of value to its shares in past 6 months, showing an annual growth rate of 57.67% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 178.90% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 47.81M for the same. And 1 analysts are in estimates of company making revenue of 55M in the next quarter. Company posted 13.53M and 49.57M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -48.07% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 64.44% while estimates for its earnings growth in next 5 years are of 9.80%.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s Major holders
Insiders are in possession of 2.16% of company’s total shares while institution are holding 111.91 percent of that, with stock having share float percentage of 114.38%. Investors also watch the number of corporate investors in a company very closely, which is 111.91% institutions for Arcutis Biotherapeutics Inc that are currently holding shares of the company. JENNISON ASSOCIATES LLC is the top institutional holder at ARQT for having 11.57 million shares of worth $107.62 million. And as of 2024-06-30, it was holding 9.3712 of the company’s outstanding shares.
The second largest institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, which was holding about 10.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.1021 of outstanding shares, having a total worth of $93.04 million.
